Share on StockTwits

Auspex Pharmaceuticals’ (NASDAQ:ASPX) lock-up period is set to end on Monday, August 4th. Auspex Pharmaceuticals had issued 7,000,000 shares in its initial public offering on February 5th, Stock Ratings News reports. The total size of the offering was $84,000,000 based on an initial share price of $12.00. After the expiration of Auspex Pharmaceuticals’ lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Separately, analysts at Robert W. Baird raised their price target on shares of Auspex Pharmaceuticals from $34.00 to $42.00 in a research note on Friday, July 11th. They now have an “outperform” rating on the stock.

Auspex Pharmaceuticals (NASDAQ:ASPX) traded down 6.15% during mid-day trading on Friday, hitting $17.09. The stock had a trading volume of 190,100 shares. Auspex Pharmaceuticals has a 52-week low of $13.25 and a 52-week high of $35.78. The stock has a 50-day moving average of $21.1 and a 200-day moving average of $23.20. The company’s market cap is $389.1 million. Auspex Pharmaceuticals also was the target of a significant growth in short interest in July. As of July 15th, there was short interest totalling 795,897 shares, a growth of 48.4% from the June 30th total of 536,475 shares. Currently, 7.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 216,916 shares, the days-to-cover ratio is currently 3.7 days.

Auspex Pharmaceuticals (NASDAQ:ASPX) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.81) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.39) by $0.42. Analysts expect that Auspex Pharmaceuticals will post $-1.95 EPS for the current fiscal year.

Auspex Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of medicines for the treatment of orphan diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.